Emergency use authorisation for Zydus Cadila's three dose Covid-19 vaccine, ZyCoV-D has been suggested by the subject expert team of the Indian drug regulator, as reported by CNBC-TV-18 on Friday.
Additional data needs to be submitted for the 2-dose course of its vaccine according to the committee, CNBC-TV-18 mentioned in a tweet. If it gets approval, it will be the first vaccine that can be given to 12-year olds and above.
The Ahmedabad-based drugmaker namely Cadila Healthcare Ltd applied for clearance of ZyCoV-D on July 1 basis the efficacy rate of 66.6% found in the late stage trial of more than 28,000 candidates across the nation.
Cadila Healthcare Ltd conducted the largest clinical trial spread over 50 centres. Once approved, Zydus Cadila could be the second home-grown shot to get emergency usage clearance after Covaxin, in India. Also this was the first time adolescent population was a part of the clinical trial.
Zydus developed the Covid-19 vaccine, ZyCov-D, with the support of the central government’s Department of Biotechnology and the Indian Council of Medical Research.
Additional data needs to be submitted for the 2-dose course of its vaccine according to the committee, CNBC-TV-18 mentioned in a tweet. If it gets approval, it will be the first vaccine that can be given to 12-year olds and above.
#CNBCTV18Exclusive | Subject Expert Committee recommends EUA for ZyCoV-D; Cadila Health’s 3-dose COVID vaccine, sou… https://t.co/K7u6mSvDQ3
— CNBC-TV18 (@CNBCTV18Live) 1629445231000The Ahmedabad-based drugmaker namely Cadila Healthcare Ltd applied for clearance of ZyCoV-D on July 1 basis the efficacy rate of 66.6% found in the late stage trial of more than 28,000 candidates across the nation.
Cadila Healthcare Ltd conducted the largest clinical trial spread over 50 centres. Once approved, Zydus Cadila could be the second home-grown shot to get emergency usage clearance after Covaxin, in India. Also this was the first time adolescent population was a part of the clinical trial.
Zydus developed the Covid-19 vaccine, ZyCov-D, with the support of the central government’s Department of Biotechnology and the Indian Council of Medical Research.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.